Cancer Immunology Immunotherapy

Founding Editor
G. Mathé

Other Biological Response Modifications

Volume 25 1987

Editors in Chief

R. W. Baldwin E. Mihich

Editorial Board

R. Arnon Rehovot
R. Bast Durham
N. Bloksma Utrecht
T. Boon Brussels
E. C. Borden Madison
V. S. Byers Berkeley
T. Carey Ann Arbor
M. Cheever Seattle
M. Colnaghi Milan
G. A. Currie Oxted, Surrey
W. Den Otter Utrecht
S. Dray Chicago
S. Eccles Sutton, Surrey
I. Fidler Houston
A. Goldstein Washington
E. Grimm Houston
K. Hellström Seattle
J. Kieler Copenhagen
H. Kirchner Heidelberg
H. Kobayashi Sapporo
M. Mastrangelo Philadelphia
J. McVie Amsterdam
M. Micksche Vienna
P. Minden La Jolla
M. Mitchell Los Angeles
R. J. North Saranac Lake
H. Ozer Buffalo
G. Parmiani Milan
H. M. Pinedo Amsterdam
T. J. Priestman Birmingham
R. Rees Sheffield
P. Rümke Amsterdam
D. Scott Rochester
K. Sikora London
G. Stevenson Southampton
F. Vánky Stockholm
B. Vose Cheshire
Y. Yagi Kamakura City
K. Yamamoto Kanazawa
Y. Yamamura Osaka

Springer International

Cancer Immunology Immunotherapy

Other Biological Response Modifications

This journal was founded in 1976. Founding editor: G. Mathé
Editors: R. W. Baldwin, E. Mihich
Published by Springer International

Copyright

Submission of a manuscript implies: that the work described has not been published before (except in the form of an abstract or as part of a published lecture, review, or thesis); that it is not under consideration for publication elsewhere; that its publication has been approved by all coauthors, if any, as well as by the responsible authorities at the institute where the work has been carried out; that, if and when the manuscript is accepted for publication, the authors agree to automatic transfer of the copyright to the publisher; and that the manuscript will not be published elsewhere in any language without the consent of the copyright holders.

All articles published in this journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article (e. g., as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfilm, in electronic data bases, video disks, etc., without first obtaining written permission from the publisher.

The use of general descriptive names, trade names, trademarks, etc., in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

While the advice and information in this journal is believed to be true and accurate at the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Special regulations for photocopies in the USA: Photocopies may be made for personal or inhouse use beyond the limitations stipulated under Section 107 or 108 of U. S. Copyright Law, provided a fee is paid. This fee is US $ 0.20 per page, or a minimum of US $ 1.00 if an article contains fewer than five pages. All fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA, stating the ISSN 0340-7004, the volume, and the first and last page numbers of each article copied. The copyright owner's consent does not include copying for general distribution, promotion, new works, or resale. In these cases, specific written permission must first be obtained from the publisher.

Printed in Germany by E. Kieser GmbH Graphischer Betrieb, D-8902 Neusäß

© Springer-Verlag Berlin Heidelberg 1987

Contents of volume 25

No. 1 (pp 1– 68) published July 2, 1987
No. 2 (pp 69–156) published September 13, 1987
No. 3 (pp 157–274) published November 12, 1987

Aaskoven O → Blomgren H, et al. 41
Abdul Hamied TA, Turk JL: Enhancement of interleukin-2 release *in rats by treatment with bleomycin and Adriamycin in* vivo 245
Abo T → Nara K, et al. 126
Akiyoshi T → Takamuku K, et al. 137
Alvarez R → Subiza JL, et al. 87
Ames IH, Gates CE, Garcia AM, John PA, Henning AK, Tomar RH: Lysis of fresh murine mammary tumor cells by syngeneic natu*ral killer cells and lymphokine-activated killer cells 161*
Anderson TM, Ibayashi Y, Holmes EC, Golub SH: Modification of natural killer activity of lymphocytes infiltrating human lung cancers 65
Arnon R → Schechter B, et al. 225
Ashman LK, Kriek GW, Cooper SJ, O'Keefe DE: Requirements for the stimulation of allogeneic T lymphocytes by acute non-lym*phoblastic leukaemia cells 250*
Aukerman SL, Fidler IJ: Antigenicity of UV radiation-induced murine tumors correlates positively with the level of adenosine deaminase activity 175

Baldwin RW → Price MR, et al. 10
Barker E, Mokyr MB: Some characteristics of the in vivo antitumor immunity exhibited by mice cured of a large MOPC-315 tumor by a low dose of melphalan 215
Barot-Ciorbaru R, Cornil I, Grand-Perret T, Poupon M-F: Antimetastatic effect of immunomodulators from *Nocardia opaca* in mice *and rats activation of peritoneal macrophages by these fractions* 111
Beddingfield N → Schantz SP, et al. 141
Bergmann L, Mitrou PS, Demmer-Dieckmann M, Ruhmann FT, *Weidmann E: Impaired T- and B-cell functions in patients with* Hodgkin's disease reduced mitogenic responsibility and I1-2 production is not caused by defective $CD4^+$-cells 59
Blättler WA → Scott CF Jr, et al. 31
Blomgren H, Näslund I, Esposti P-L, Johansen L, Aaskoven O: Adjuvant Bestatin immunotherapy in patients with transitional cell carcinoma of the bladder. Clinical results of a randomized trial 41
Bolender S → Scott CF Jr, et al. 31
Bonnem EM → Thompson JA, et al. 47
Bottari V → De Rossi G, et al. 133
Bröcker E-B, Zwadlo G, Suter L, Brune M, Sorg C: Infiltration of primary and metastatic melanomas with macrophages of the 25F9-positive phenotype 81
Brookes RH, Kew MC, Rabson AR: Depressed natural cytotoxicity but normal natural killer cytotoxic factor (NKCF) production by mononuclear cells derived from patients with hepatocellular carcinoma 149
Brown BW → Schantz SP, et al. 141
Brune M → Bröcker E-B, et al. 81
Bursuker I → Kaymakcalan Z, et al. 69
Byers VS → Price MR, et al. 10

Capone PM, Kadohama N, Chu TM: Immunotherapy in a spontaneously developed murine mammary carcinoma with syngeneic monoclonal antibody 93
Casson E → Kuppner M, et al. 209
Chari RVJ → Scott CF Jr, et al. 31
Chott A → Ludwig H, et al. 266
Chu TM → Capone PM, et al. 93
Coates A → Hersey P, et al. 257
Collins C → Thompson JA, et al. 47
Collins DP: Effects of L_2C leukemia on macrophage-mediated responses 75
Coll J → Subiza JL, et al. 87
Cooper SJ → Ashman LK, et al. 250
Cornil I → Barot-Ciorbaru R, et al. 111
Cox WW → Thompson JA, et al. 47
Crowther D → Wagstaff J, et al. 54

Darrow TL → Stuhlmiller GM, et al. 193
De la Concha EG → Subiza JL, et al. 87
Demmer-Dieckmann M → Bergmann L, et al. 59
De Rossi G, De Sanctis G, Bottari V, Tribalto M, Lopez M, Petrucci MT, Fontana L: Surface markers and cytotoxic activities of lymphocytes in monoclonal gammopathy of undetermined significance and untreated multiple myeloma. Increased phytohemagglutinin-induced cellular cytotoxicity and inverted helper/ *suppressor cell ratio are features common to both diseases* 133
De Sanctis G → De Rossi G, et al. 133

Edwards A → Hersey P, et al. 257
Edwards S → Price MR, et al. 10
Eggermont AMM, Sugarbaker PH, Marquet RL, Jeekel J: Synergis*tic antitumor activity of cyclophosphamide and ABPP in the* treatment of established and advanced tumors in murine tumor models 16
Endo N, Takeda Y, Kishida K, Kato Y, Saito M, Umemoto N, Hara T: Target-selective cytotoxicity of methotrexate conjugated with monoclonal anti-MM46 antibody 1
Eremin O → Kuppner M, et al. 209
Esposti P-L → Blomgren H, et al. 41

Fefer A → Thompson JA, et al. 47
Fidler IJ → Aukerman SL 175
Figlin RA → Lindemann RA, et al. 153
Flener R → Ludwig H, et al. 266
Fontana L → De Rossi G, et al. 133
Fritz E → Ludwig H, et al. 266
Fujii M → Nara K, et al. 126
Fujiwara H → Sano S, et al. 105
Fujiwara H → Sano H, et al. 180
Fujiwara H → Nakajima H, et al. 201

Garcia AM → Ames IH, et al. 161
Gates CE → Ames IH, et al. 161
Gauthier MN → Scott CF Jr, et al. 31
Gisslinger H → Ludwig H, et al. 266
Goldmacher VS → Scott CF Jr, et al. 31
Golub SH → Anderson TM, et al. 65
Golub SH → Lindemann RA, et al. 153
Gotoh T → Nakajima H, et al. 201
Grand-Perret T → Barot-Ciorbaru R, et al. 111

Haimovich J → Schechter B, et al. 225
Hamaoka T → Sano S, et al. 105
Hamaoka T → Sano H, et al. 180
Hamaoka T → Nakajima H, et al. 201
Hamuro J → Yoshimoto R, et al. 25
Hara T → Endo N, et al. 1
Haupt DM → Stuhlmiller GM, et al. 193
Hennig AK → Ames IH, et al. 161
Henningsson CM, Selvaraj S, MacLean GD, Suresh MR, Noujaim AA, Longenecker BM: T cell recognition of a tumor-associated glycoprotein and its synthetic carbohydrate epitopes: stimulation of anticancer T cell immunity in vivo 231
Hersey P, Edwards A, Coates A, Shaw H, McCarthy W, Milton G: Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma. Treatment of stage II melanoma with viral lysates 257

Hiramoto Y, Sugimachi K: Effect of glucocorticoid deficiency after adrenalectomy on antitumor immunity 157
Holmes EC → Anderson TM, et al. 65

Ibayashi Y → Anderson TM, et al. 65
Isawa M-A → Yoshimoto R, et al. 25
Isumi S → Nakajima H, et al. 201
Izumi Y → Sano S, et al. 105
Izumi Y → Nakajima H, et al. 201

Jacobs E → Price MR, et al. 10
Jeekel J → Eggermont AMM, et al. 16
Jeekel J → Singh SK, et al. 242
Jenkins JA → Lindemann RA, et al. 153
Johansen L → Blomgren H, et al. 41
John PA → Ames IH, et al. 161

Kadohama N → Capone PM, et al. 93
Kato S → Okada H, et al. 7
Kato Y → Endo N, et al. 1
Katsumi M → Yamaue H, et al. 169
Kaymakcalan Z, Spitalny GL, Bursuker I: In vitro expression of secondary antitumor immunity by in vivo tumor-sensitized T cells: Inhibition by tumor-induced suppressor T cells 69
Kew MC → Brookes RH, et al. 149
Kishida K → Endo N, et al. 1
Kishimoto S → Sakatani M, et al. 119
Kondoh N → Yoshimoto R, et al. 25
Kon M → Nara K, et al. 126
Kosugi A → Sano H, et al. 180
Kriek GW → Ashman LK, et al. 250
Kuppner M, Wilkinson S, Casson E, Eremin O: In vitro generation of tumour-specific lymphocyte reactivity to colonic carcinoma cells comparison with normal colonic mucosa cells 209
Kuribayashi K → Yamaue H, et al. 169

Lambert JM → Scott CF Jr, et al. 31
Lindemann RH, Jenkins JA, Figlin RA, Golub SH: Application of a new method for detecting the phenotype of target binding cells 153
Lindgren CG → Thompson JA, et al. 47
Linkesch W → Ludwig H, et al. 266
Lira E → Schantz SP, et al. 141
Longenecker BM → Henningsson CM, et al. 231
Lopez M → De Rossi G, et al. 133
Loynds P → Wagstaff J, et al. 54
Ludwig H, Linkesch W, Gisslinger H, Fritz E, Sinzinger H, Radaszkiewicz T, Chott A, Flener R, Micksche M: Interferon-alfa corrects thrombocytosis in patients with myeloproliferative disorders 266

MacLean GD → Henningsson CM, et al. 231
Marquet RL → Eggermont AMM, et al. 16
Marquet RL → Singh SK, et al. 242
Masuno T → Sakatani M, et al. 119
Matsuzaki T, Yokokura T: Inhibition of tumor metastasis of Lewis lung carcinoma in C57BL/6 mice by intrapleural administration of *Lactobacillus casei* 100
McCarthy W → Hersey P, et al. 257
Micksche M → Ludwig H, et al. 266

Milton G → Hersey P, et al. 257
Mitrou PS → Bergmann L, et al. 59
Mokyr MB → Barker E 215
Morita T → Nara K, et al. 126

Nakajima H → Sano S, et al. 105
Nakajima H, Izumi Y, Sugihara S, Satoh Y, Isumi S, Gotoh T, Fujiwara H, Hamaoka T: Studies on macrophage-activating factor (MAF) in antitumor immune responses. II. Molecular characterization of MAF produced by the tumor-immune Lyt-1^+2^- T cell subset 201
Nara K, Odagiri H, Fujii M, Yamanaka Y, Yokoyama M, Morita T, Sasaki M, Kon M, Abo T: Increased production of tumor necrosis factor and prostaglandin E_2 by monocytes in cancer patients and its unique modulation by their plasma 126
Näslund I → Blomgren H, et al. 41
Nelmes P → Wagstaff J, et al. 54
Neraas KA → Thompson JA, et al. 47
Ngwenya BZ → Yamamoto N, et al. 185
Nishihara T → Yamaue H, et al. 169
Noujaim AA → Henningsson CM, et al. 231

Odagiri H → Nara K, et al. 126
Ogura T → Sakatani M, et al. 119
Okada H, Wakamiya N, Okada N, Kato S: Sensitization of human tumor cells to homologous complement by vaccinia virus treatment 7
Okada N → Okada H, et al. 7
O'Keefe DE → Ashman LK, et al. 250

Pauzner R → Schechter B, et al. 225
Pawluczyk IZA → Price MR, et al. 10
Petrucci MT → De Rossi G, et al. 133
Pieringer RA → Yamamoto N, et al. 185
Poupon M-F → Barot-Ciorbaru R, et al. 111
Price MR, Edwards S, Jacobs E, Pawluczyk IZA, Byers VS, Baldwin RW: Mapping of monoclonal antibody-defined epitopes associated with carcinoembryonic antigen, CEA 10

Rabson AR → Brookes RH, et al. 149
Radaszkiewicz T → Ludwig H, et al. 266
Ruhmann FT → Bergmann L, et al. 59

Saito K → Yamaue H, et al. 169
Saito M → Endo N, et al. 1
Sakatani M, Ogura T, Masuno T, Kishimoto S, Yamamura Y: Effect of *Nocardia rubra* cell wall skeleton on augmentation of cytotoxicity function in human pleural macrophages 119
Sano H, Kosugi A, Sano S, Fujiwara H, Hamaoka T: The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. II. Establishment of tumor-specific immunotherapy models utilizing MDP hapten-reactive T cell activity 180
Sano S, Izumi Y, Sugihara S, Nakajima H, Fujiwara H, Hamaoka T: The generation of tumor-specific in vivo protective immunity in the tumor mass from mice rendered tolerant to tumor antigens 105
Sano S → Sano H, et al. 180
Sasaki M → Nara K, et al. 126
Satoh Y → Nakajima H, et al. 201
Schantz SP, Brown BW, Lira E, Taylor DL, Beddingfield N: Evidence for the role of natural immunity in the control of metastatic spread of head and neck cancer 141
Schechter B, Pauzner R, Arnon R, Haimovich J, Wilchek M: Selective cytotoxicity against tumor cells by cisplatin complexed to antitumor antibodies via carboxymethyl dextran 225
Scott CF Jr, Goldmacher VS, Lambert JM, Chari RVJ, Bolender S, Gauthier MN, Blättler WA: The antileukemic efficacy of an immunotoxin composed of a monoclonal anti-Thy-1 antibody disulfide linked to the ribosome-inactivating protein gelonin 31
Seigler HF → Stuhlmiller GM, et al. 193
Selvaraj S → Henningsson CM, et al. 231
Sery TW → Yamamoto N, et al. 185
Shaw H → Hersey P, et al. 257
Singh SK, Marquet RL, Westbroek DL, Jeekel J: Abrogation of the tumor promoting effect of allogeneic blood transfusion by polyadenylic-polyuridylic acid (poly A–poly U) 242
Sinzinger H → Ludwig H, et al. 266
Smith D → Wagstaff J, et al. 54
Sorg C → Bröcker E-B, et al. 81
Spitalny GL → Kaymakcalan Z, et al. 69

Stuhlmiller GM, Darrow TL, Haupt DM, Seigler HF: Immune response of chimpanzee to purified melanoma 250 kilodalton tumor-associated antigen 193
Subiza JL, Coll J, Alavarez R, Valdivieso M, De la Concha EG: IgM response and resistance to ascites tumor growth 87
Sugarbaker PH → Eggermont AMM, et al. 16
Sugihara S → Sano S, et al. 105
Sugihara S → Nakajima H, et al. 201
Sugimachi K → Hiramoto Y 157
Suresh MR → Henningsson CM, et al. 231
Suter L → Bröcker E-B, et al. 81

Tabuse K → Yamaue H, et al. 169
Tabuse Y → Yamaue H, et al. 169
Takamuku K, Akiyoshi T, Tsuji H: Antibody-dependent cell-mediated cytotoxicity using a murine monoclonal antibody against human colorectal cancer in cancer patients 137
Takeda Y → Endo N, et al. 1
Taylor DL → Schantz SP, et al. 141
Thompson JA, Cox WW, Lindgren CG, Collins C, Neraas KA, Bonnem EM, Fefer A: Subcutaneous recombinant gamma interferon in cancer patients: toxicity, pharmacokinetics, and immunomodulatory effects 47
Tomar RH → Ames IH, et al. 161
Tribalto M → De Rossi G, et al. 133
Tsuji H → Takamuku K, et al. 137
Turk JL → Abdul Hamied TA 245

Umemoto N → Endo N, et al. 1

Valdivieso M → Subiza JL, et al. 87

Wagstaff J, Smith D, Nelmes P, Loynds P, Crowther D: A phase I study of recombinant interferon gamma administered by s.c. injection three times per week in patients with solid tumours 54
Wakamiya N → Okada H, et al. 7
Weidmann E → Bergmann L, et al. 59
Westbroek DL → Singh SK, et al. 242
Wilchek M → Schechter B, et al. 225
Wilkinson S → Kuppner M, et al. 209

Yamamoto N, Ngwenya BZ, Sery TW, Pieringer RA: Activation of macrophages by ether analogues of lysophospholipids 185
Yamamura Y → Sakatani M, et al. 119
Yamanaka Y → Nara K, et al. 126
Yamaue H, Katsumi M, Tabuse K, Tabuse Y, Kuribayashi K, Nishihara T, Saito K: Induction of activated natural killer cells from murine spleen cells primed in vivo and subsequently challenged in vitro with the streptococcal preparation OK432 169
Yokokura T → Matsuzaki T 100
Yokoyama M → Nara K, et al. 126
Yoshimoto R, Kondoh N, Isawa M-A, Hamuro J: Plant lectin, ATF1011, on the tumor cell surface augments tumor-specific immunity through activation of T cells specific for the lectin 25

Zwadlo G → Bröcker E-B, et al. 81

This volume contains Abstracts of the 1st Meeting of the Universities of the Upper-Rhine Area: Macrophages and immunity, perspectives in cancer and tissue regeneration. Council of Europe, Strasbourg, March 20, 1987. C1–C6

Indexed in *Current Contents*

Subject index of volume 25

Adenosine deaminase 175
Adjuvant therapy 41
Adrenalectomy 157
Adriamycin 245
Alkyl lipids 185
Antibody 1, 225
– ADCC 133, 137
– IgM 87
– monoclonal 1, 10, 31, 93, 137
Antigen
– carbohydrate 87
– carcinoembryonic 10
– HLA 250
– tumor associated 193

Bestatin 41
Bladder cancer 41
Bleomycin 245
Blood transfusion 242

Cisplatin 225
Colorectal cancer 137, 209
Complement 7
Cyclophosphamide 16

Fc receptor 185

Gammopathy
– malignant 133
Gelonin 31
Glucocorticoid 157

Head and neck cancer 141
Hepatocellular carcinoma 149
Hodgkin's disease 59

Immune deficiency 59
Immunity
– tumor 25, 105, 157, 215, 231
Immunoglobulin production 59
Immunotargeting 225
Immunotherapy 54, 93, 180, 257
Immunotoxin 31
Interferon 153, 169, 266
– gamma 47, 54, 119, 201
Interleukins 59
Interleukin 1 250
Interleukin 2 169, 245

Lactobacillus casei 100
LAK cells 161
Lectin 25
Leukemia 75
– myeloid 250
Lung cancer 65
– Lewis lung carcinoma 100, 111
Lymphocyte
– HLA antigens 250
– T cells 25, 59, 69, 201, 231
– T cells helper 180

Macrophage 81, 119
– activation 185
– activating factor 201
– peritoneal 111
Melanoma 81, 193, 257
Melphalan 215
Metastasis 100, 111, 141
Methotrexate 1
Monoclonal antibody 1, 10, 31, 93, 137
Monocytes 126
Muramyl dipeptide 180
Myeloma
– multiple 133
Myeloproduction disorders 266

Natural killer cell 133, 141, 149, 161, 169
– activity 65
– binding 153
– cytotoxic factor 149
Nocardiae opaca 111
Nocardia rubra cell wall skeleton 119

OK-432 169

Poly A – poly U 242
Prostaglandin E_2 126

Suppressor cells 69

Tumor
– immunity 7, 16, 25, 105, 157, 215, 231
– infiltrating lymphoid cells 105
– promotion 242
– synthetic associated glycoconjugates 231
Tumor necrosis factor 126

Vaccinia virus 7